Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 1c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.52, $0.01 better than the analyst estimate of $0.51. Revenue for the quarter came in at $50.1 million versus the consensus estimate of $52.52 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Signet shares jump on Q2 profit beat, raised annual guidance
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance